DNA Methyltransferase 3A : a Significant Target for the Discovery of Inhibitors as Potent Anticancer Drugs
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
DNA methyltransferase (DNMT) is a conserved family of Cytosine methylases, which plays a crucial role in the regulation of Epigenetics. They have been considered promising therapeutic targets for cancer. Among the DNMT family, mutations in the DNMT3A subtype are particularly important in hematologic malignancies. The development of specific DNMT3A subtype inhibitors to validate the therapeutic potential of DNMT3A in certain diseases is a significant task. In this review, we summarized the small molecule inhibitors of DNMT3A discovered in recent years and their inhibitory activities, and classified them based on their inhibitory mechanisms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Mini reviews in medicinal chemistry - (2023) vom: 25. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Feng, Qixun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
Date Revised 29.08.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/1389557523666230825100246 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361401639 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361401639 | ||
| 003 | DE-627 | ||
| 005 | 20231226085048.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389557523666230825100246 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361401639 | ||
| 035 | |a (NLM)37642180 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Feng, Qixun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a DNA Methyltransferase 3A |b a Significant Target for the Discovery of Inhibitors as Potent Anticancer Drugs |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a DNA methyltransferase (DNMT) is a conserved family of Cytosine methylases, which plays a crucial role in the regulation of Epigenetics. They have been considered promising therapeutic targets for cancer. Among the DNMT family, mutations in the DNMT3A subtype are particularly important in hematologic malignancies. The development of specific DNMT3A subtype inhibitors to validate the therapeutic potential of DNMT3A in certain diseases is a significant task. In this review, we summarized the small molecule inhibitors of DNMT3A discovered in recent years and their inhibitory activities, and classified them based on their inhibitory mechanisms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DNMT | |
| 650 | 4 | |a DNMT inhibitors | |
| 650 | 4 | |a DNMT3A | |
| 650 | 4 | |a SAM | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a epigenetic modification | |
| 700 | 1 | |a Duan, Honggao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Xinglong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yuning |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jinda |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Haoge |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Guoliang |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Xuefei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mini reviews in medicinal chemistry |d 2001 |g (2023) vom: 25. Aug. |w (DE-627)NLM121595404 |x 1875-5607 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:25 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389557523666230825100246 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 25 |c 08 | ||